99198-80-8

Usage

Uses

Used in Pharmaceutical Industry:
1-CBZ-4-(3-HYDROXY-PROPYL)-PIPERIDINE serves as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties. 1-CBZ-4-(3-HYDROXY-PROPYL)-PIPERIDINE's reactivity enables chemists to modify its structure to create a wide range of pharmaceutically relevant molecules.
Used in Organic Synthesis:
In the field of organic synthesis, 1-CBZ-4-(3-HYDROXY-PROPYL)-PIPERIDINE is utilized as a building block for the creation of complex organic compounds. Its hydroxypropyl group and piperidine core provide a foundation for further chemical reactions, allowing for the synthesis of a diverse array of organic molecules with potential applications in various industries.
Used in Research and Development:
1-CBZ-4-(3-HYDROXY-PROPYL)-PIPERIDINE is also employed in research and development settings, where its unique properties are explored for potential applications in new technologies and innovations. Its reactivity and structural features make it an interesting subject for scientific investigation, contributing to the advancement of knowledge in organic chemistry and related fields.

Upstream product

• 501-53-1 benzyl chloroformate 
• 156185-63-6 N-Boc-piperidin-4-yl-propanol 
• 7037-49-2 3-(piperidin-4-yl)propan-1-ol 

Downstream Products

• 120426-40-6 3-(1-benzyloxycarbonyl-4-piperidyl)propyl iodide 
• 566905-93-9 benzyl 4-{3-[bis(tert-butoxycarbonyl)amino]propyl}piperidine-N-carboxylate 
• 566906-01-2 2-(4-{3-[bis(tert-butoxycarbonyl)amino]propyl}piperidin-1-yl)ethyl 4 amino-5-chloro-2-methoxybenzoate 
• 461052-28-8 4-[3-(3-formyl-indol-1-yl)-propyl]-piperidine-1-carboxylic acid benzyl ester 
• 461052-34-6 4-[3-(3-carboxymethyl-indol-1-yl)-propyl]-piperidine-1-carboxylic acid benzyl ester 
• 461052-26-6 4-[3-(3-methoxycarbonylmethyl-indol-1-yl)-propyl]-piperidine-1-carboxylic acid benzyl ester 
• 461052-36-8 4-{3-[3-((E)-2-Carboxy-vinyl)-indol-1-yl]-propyl}-piperidine-1-carboxylic acid benzyl ester 
• 461052-30-2 benzyl 4-(3-{3-[(E)-3-ethoxy-3-oxo-1-propenyl]-1H-1-indolyl}-propyl)-1-piperidinecarboxylate 
• 461052-44-8 4-(3-{3-[(E)-2-(2-Methoxycarbonyl-1-methyl-ethylcarbamoyl)-vinyl]-indol-1-yl}-propyl)-piperidine-1-carboxylic acid benzyl ester 
• 461052-40-4 4-(3-{3-[(2-ethoxycarbonyl-ethylcarbamoyl)-methyl]-indol-1-yl}-propyl)-piperidine-1-carboxylic acid benzyl ester 
• 461052-42-6 4-(3-{3-[(E)-2-(2-Ethoxycarbonyl-ethylcarbamoyl)-vinyl]-indol-1-yl}-propyl)-piperidine-1-carboxylic acid benzyl ester 
• 461052-64-2 3-{2-[1-(3-piperidin-4-yl-propyl)-1H-indol-3-yl]-acetylamino}-2-(toluene-4-sulfonylamino)-propionic acid methyl ester 
• 461052-67-5 3-{[2-(1-{3-[1-(tert-butyloxycarbonyl)-4-piperidyl]propyl}-1H-3-indolyl)acetyl]amino}-2-{[(4-methyl-phenyl)sulfonyl]amino}propanoic acid 
• 461052-66-4 tert-butyl 4-[3-(3-{2-[(3-methoxy-2-{[(4-methylphenyl)sulfonyl]amino}-3-oxopropyl)amino]-2-oxo-ethyl}-1H-1-indolyl)propyl]-1-piperidinecarboxylate 

Relevant academic research and scientific papers

ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Substituted aryl and heteroaryl ether compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R 1, R 2, R 3, L, R 4, L 1, Q, and R 5 are as defined herein. These compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the Formula IX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

3-Amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives

Novel 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives of the formula STR1 [wherein R1 and R2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy, or both jointly form tri- or tetramethylene; R3 is hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl; R4 is hydrogen, optionally substituted alkyl, optionally substituted aralkyl or optionally substituted cycloalkylalkyl; Y is a carboxyl group which may be esterified or amidated; m is 1 or 2] and salts thereof. These compounds and salts thereof exhibits inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of circulatory diseases (e.g. hypertension, cardiopathy, cerebral apoploxy).